**Title: European Position Statement on Lung Cancer Screening.**

**Authors**

Matthijs Oudkerk 1

Anand Devaraj  2

Rozemarijn Vliegenthart  1

Thomas Henzler  3

Helmut Prosch 4

Claus Peter Heussel  5

Gorka Bastarrika  6

Nicola Sverzellati 7

Mario Mascalchi  8

Stefan Delorme  9

David R Baldwin  10

Matthew E. Callister  11

Nikolaus Becker  12

Marjolein A Heuvelmans  1

Witold Rzyman  13

Maurizio V. Infante  14

Ugo Pastorino  15

Jesper HolstPedersen  16

Eugino Paci  17

Stephen W. Duffy 18

Harry de Koning 19

John K. Field 20

1.Matthijs Oudkerk MD PhD

Rozemarijn Vliegenthart MD PhD

Marjolein A Heuvelmans MD PhD.

University of Groningen

University Medical Center Groningen

Center for Medical Imaging EB 45

Hanzeplein 1

9700RB Groningen

Email: [m.oudkerk@umcg.nl](mailto:m.oudkerk@umcg.nl)

2. Anand Devaraj MD, FRCR.

Department of Radiology,

Royal Brompton Hospital,

Sydney Street, London,

SW3 6NP, UK.

Email: [A.Devaraj@rbht.nhs.uk](mailto:A.Devaraj@rbht.nhs.uk)

3. Thomas Henzler MD

Institute of Clinical Radiology and Nuclear Medicine

University Medical Centre Mannheim, Medical Faculty Mannheim

Heidelberg University

Theodor-Kutzer-Ufer 1-3

68167 Mannheim,

Germany

Email: [Thomas.Henzler@medma.uni-heidelberg.de](mailto:Thomas.Henzler@medma.uni-heidelberg.de)

4. Helmut Prosch MD

Department of Biomedical Imaging and Image-guided Therapy

Medical University of Vienna

Vienna General Hospital

Währingergürtel 18-22

1090 Vienna, Austria

Email: [helmut.prosch@meduniwien.ac.at](mailto:helmut.prosch@meduniwien.ac.at)

5. Claus Peter Heussel MD

A Translational Research Unit, Thoraxklinik, Heidelberg University, Germany Translational Lung Research Centre Heidelberg (TLRC-H), Member of the German Centre for Lung Research (DZL), Heidelberg, Germany

B Department of Diagnostic and Interventional Radiology, University-Hospital Heidelberg

C Department of Diagnostic and Interventional Radiology with Nuclear Medicine, Thoraxklinik at University-Hospital Heidelberg

Röntgenstraße 1, 69126 Heidelberg, Germany

Email: ['heussel@uni-heidelberg.de](mailto:'heussel@uni-heidelberg.de)

6. Gorka Bastarrika MD PhD, EBCR

Department of Radiology

Clínica Universidad de Navarra

Avenida Pío XII, 36

31008 Pamplona, Spain

Email: [bastarrika@unav.es](mailto:bastarrika@unav.es)

7. Nicola Sverzellati MD

Radiology, Department of Medicine and Surgery,

University of Parma

Via Gramsci 14, 43123,

Parma,

Italy.

Email: [nicola.sverzellati@unipr.it](mailto:nicola.sverzellati@unipr.it)

8. Mario Mascalchi MD

Department of Clinical and Experimental Biomedicine

University of Florence

Florence

50100

Italy

Email: [m.mascalchi@dfc.unifi.it](mailto:m.mascalchi@dfc.unifi.it)

9. Stefan Delorme, MD

Department of Radiology;

German Cancer Research Center;

Heidelberg;

Germany.

email: [s.delorme@dkfz-heidelberg.de](mailto:s.delorme@dkfz-heidelberg.de)

10.David R Baldwin MD FRCP

Respiratory Medicine Unit

David Evans Research Centre

Nottingham University Hospitals, City Campus

Hucknall Road

Nottingham

NG5 1PB

Email: [David.Baldwin@nottingham.ac.uk](mailto:David.Baldwin@nottingham.ac.uk)

11. Matthew E. Callister MD

Department of Respiratory Medicine,

Leeds Teaching Hospitals

St James’s University Hospital

Beckett Street

Leeds LS9 7TF

UK

Email: [matthew.callister@nhs.net](mailto:matthew.callister@nhs.net)

12.Nikolaus Becker, PhD

Div. of Cancer Epidemiology,

German Cancer Research Center,

Heidelberg,

Germany

Email: [n.becker@DKFZ-Heidelberg.de](mailto:n.becker@DKFZ-Heidelberg.de)

13. Witold Rzyman MD, PhD

Department of Thoracic Surgery

Medical University of Gdańsk

Smoluchowskiego 17

80-214 Gdańsk, Poland

Email: [wrzyman@gumed.edu.pl](mailto:wrzyman@gumed.edu.pl)

14. Maurizio V. Infante, MD

Thoracic Surgery Dept.

University and Hospital Trust - Azienda Ospedaliera Universitaria Integrata

VERONA

Italy

Email: [maurizio.infante@aovr.veneto.it](mailto:maurizio.infante@aovr.veneto.it)

15.Ugo Pastorino, MD

Dept. of Thoracic Surgery,

Istituto Nazionale Tumori,

Milan,

Italy

Email: ugo.pastorino@istitutotumori.mi.it

16. Jesper Holst Pedersen MD, DMSCi

Department of Cardiothoracic Surgery R-2152

Rigshospitalet, University of Copenhagen

Blegdamsvej 9

DK-2100 Copenhagen

Denmark

Email: [jesper.holst.pedersen@rh.regionh.dk](mailto:jesper.holst.pedersen@rh.regionh.dk)

17. Eugenio Paci, MD, (Retired)

ISPO Cancer Research and Prevention Institute Tuscany Region,

Florence

Italy

Email: [paci.eugenio@gmail.com](mailto:paci.eugenio@gmail.com)

18.Stephen W. Duffy PhD

Wolfson Institute of Preventive Medicine,

Barts and The London School of Medicine and Dentistry,

Queen Mary University of London, Charterhouse Square,

London

EC1M 6BQ

Email: [s.w.duffy@qmul.ac.uk](mailto:s.w.duffy@qmul.ac.uk)

19. Harry J. de Koning, MD, PhD,

Department of Public Health,

Erasmus MC, Rotterdam,

The Netherlands.

Email: [h.dekoning@erasmusmc.nl](mailto:h.dekoning@erasmusmc.nl)

20. John K Field PhD FRCPath.

The Roy Castle Lung Cancer Research Programme

Department of Molecular and Clinical Cancer Medicine,

The University of Liverpool

Liverpool

L7 8TX

UK

Email : [J.K.Field@liv.ac.uk](mailto:J.K.Field@liv.ac.uk)

Correspondence to:

Professor John K Field PhD FRCPath.

The Roy Castle Lung Cancer Research Programme

Department of Molecular and Clinical Cancer Medicine

The University of Liverpool

6 West Derby St

Liverpool

7 8TX

UK

Email : [J.K.Field@liv.ac.uk](mailto:J.K.Field@liv.ac.uk)

**Introduction**

Lung cancer screening with low dose computed tomography (LDCT) saves lives and it is only a matter of time before it is embraced by national health organisations throughout Europe. The evidence from the NLST trial on reduction in mortality and from seven pilot trials within Europe on other aspects of screening, have provided sufficient evidence for Europe to start planning for lung cancer screening now; whilst mortality data from NELSON are awaited.

This is the rationale for an EU Position Statement (EUPS) that describes the current status and sets out the essential elements needed to ensure the development of effective European screening programmes. The EUPS expert group comprises individuals from eight European countries who have been actively engaged in the planning and execution of the randomised controlled European screening trials, those actively engaged with the clinical management of patients with lung cancer and lung nodules, and those that have developed relevant clinical guidelines; they represent all the specialties and professions involved in delivering successful lung cancer screening programmes in Europe. The emphasis for this EU position statement focuses on the actual implementation of CT lung cancer screening programmes in Europe by radiologists supported by epidemiologists, pulmonologists and thoracic surgeons, in the full context of clinical lung cancer diagnosis and treatment. We performed a comprehensive literature search for papers on lung cancer screening and through in-depth discussions developed this EUPS consensus.

The structure of the EUPS document reflects the evidence addressing the major questions concerning the delivery of a successful screening intervention but also highlights the issues that still need to be resolved. The contributions to the EUPS were provided by a team of clinicians and scientists expert in CT as the method of choice for lung cancer screening. The requirement for a EUPS stems from the need to provide European recommendations on CT screening that will assist the EU commission and national health agencies in starting planning implementation of lung cancer screening within the next two years and to avoid opportunistic uncontrolled screening. Since the publication of the NLST results in 2011, it is now crucial that we have a EUPS consensus.

The focus of the EUPS is limited to lung cancer screening with LDCT and early detection of lung nodules prior to clinical work-up, but does not address the entirety of work-up and treatment choices. It is highly unlikely that there will be any new randomized controlled LDCT screening trials powered to allow conclusions about mortality reduction, so recommendations are based on the current evidence. Existing evidence provided by a number of studies is sufficient to make recommendations concerning the minimization of false positive results in both screen-detected nodules and for clinically detected nodules identified in a non-screen environment. The need for non-contrast-enhanced low-dose interval imaging should not be considered a false positive test, as the individual is not undergoing an invasive clinical workup and therefore the chance of physical harm is very low. Furthermore the evidence shows that psychological distress is transient and smoking cessation rates are higher amongst subjects requiring interval imaging.

The position statement represents a balance of the available evidence and therefore reflects (a) what we have good evidence for, (b) where further evidence is needed to implement effective screening programmes, and (c) where practical implications for lung cancer screening can already be drawn from current knowledge and state of the art.

1. **Current diagnostic tests for lung cancer detection**

*Computed tomography is the only early detection method suitable for national lung cancer screening programmes.*

Computed tomography has evolved as the prime method for lung cancer screening. Evidence from previous lung cancer screening trials in the 1980’s on chest X-ray with and without sputum cytology demonstrated that there was no survival advantage,1,2 and resulted in inactivity in this field of research for more than two decades. The first publication in 1999 on lung CT screening ignited this modality of lung cancer screening again.3 Other diagnostic methods may have a future potential in lung cancer screening but currently there no trials to support them.4

Earlier trials using CT provided evidence, not only for the likely effectiveness, but also a great deal about the natural history of the disease. The debate continued about the ability of CT screening to reduce mortality until the US National Lung Cancer Screening Trial (NLST), that randomized 53454 subjects was stopped one year earlier than planned because the stop criteria of a 20% reduction in lung cancer mortality rate compared with that achieved by screening with chest X-ray had been reached in a periodic planned interim analysis; the trial also showed a 6.7% reduction in all-cause mortality.5

There is increasing evidence of the effectiveness of CT screening from several pilot trials in Europe and from the current NELSON publications, Table 1. However, we need to remain aware of the implications and problems associated with the work-up of suspicious nodules (i.e. invasiveness of biopsies, waiting time until final decision etc.).

The high false-positive rates both in the initial screening and subsequent screening rounds, as reported in the NLST, need to be reduced to ensure minimal harmful impact on the screenees. This is best achieved by accurate interval imaging using the latest and most accurate methods, particularly semi-automated volumetric analysis rather than manual maximum diameter measurements as already implemented by a number of trials.6–8 Furthermore, the definition of false positives also has a major bearing on how we interpret false-positive data. NELSON,9 MILD,10 and UKLS7 define false positives from their baseline data, as those requiring referral to the pulmonologist and further diagnostic investigation (3.5%), but who subsequently did not have lung cancer This is in contrast to the NLST, where every individual with a repeat CT scan prior to a repeat annual screen, was considered positive (24%, of which 96% were false positive with unnecessary CT examinations and a related radiation burden). In NLST, a positive screen included all CTs that showed a nodule 4mm or more in diameter and since publication of NLST, the NELSON study has shown that nodules smaller than 5mm (or 100mm3) do not confer a greater risk of malignancy at baseline.

No other technology is currently available that can replace CT screening. Emerging technologies need to undergo the same scrutiny that has been applied to CT screening. However, if a new emerging technology is considered, it must be compared to CT screening in a randomized controlled trial (RCT) and the negative predictive value (NPV) should be near 100% and positive predictive value (PPV) should be higher than CT screening. Some technologies might be applied as an adjunct to CT screening (see section 3).

1. **Outcomes of lung cancer screening trials**

*The outcomes of lung CT screening trials have impact on implementation.*

The outcomes of a wide variety of lung cancer screening trials give insight as to how to implement lung cancer screening in differing countries in Europe and the optimal set-up for population as well as single centre screening in Europe. We have learnt a great deal about each stage of the lung cancer CT screening pathway and the management decisions required.11 Current trials have provided us with an insight into risk assessment, CT screen nodule management, multidisciplinary team (MDT) work-up, surgical interventions, as well as psychological impact on the participants and cost effectiveness.

Several nationally funded randomized studies have already been undertaken in Europe (DANTE,12 DLCST,13 ITALUNG,14 LUSI,8 MILD,15 NELSON,6 and UKLS.7,16 Their results, individually and when pooled, will all contribute to the implementation of CT screening in Europe. The only European fully powered RCT that will provide mortality and cost effectiveness data is NELSON, although we do have sufficient data to start planning; the results from NLST alone have been sufficient for LDCT screening to start in the US and Canada.

The incorporation of coronary artery calcification (CAC) score and emphysema assessment on LDCT imaging, may enhance the cost-effectiveness and attractiveness LDCT lung cancer screening.17 COPD and emphysema are the strongest lung cancer risk predictors and together with cardiovascular disease all three imaging biomarkers have a substantial impact not only on morbidity but also, independently, on overall mortality.18,19

1. **Lung cancer risk prediction modelling**

*Future Lung cancer CT screening programmes should embrace the use of risk prediction modelling to select high risk populations.*

The concept of clearly defining the target population for lung cancer screening is gaining weight, as selection based only on age, as in most other cancer screening scenarios (e.g. breast, colon) is insufficient in lung cancer because of other powerful risk factors, the most important of which is exposure to tobacco smoke. The other major risk factors which are now also taken into account include; History of respiratory diseases (COPD, emphysema, bronchitis, pneumonia and TB), history of previous malignancy, family history of lung cancer (first degree relative greater or less than 60 years), exposure to asbestos. There are several published multivariable risk prediction models, but only two have so far been used to select subjects for screening in a clinical trial. Risk prediction models have been tested in the NLST dataset, demonstrating that the NLST selection criteria could have been improved, including the USPSTF recommendations, if a risk model had been implemented.20–22 The LLP risk model (LLPv2) is the only risk model used to date to select subjects for a lung cancer screening RCT. A higher percentage of participants were identified with lung cancer at baseline compared to baseline NLST and NELSON. The cut-off of the LLPv2 model of 5% over 5 years is currently being validated in the Liverpool Health Lung Project (LHLP).7,23–25 The LLP previously compared favourably with the Spitz and Bach models.26 The LLP was validated in the UK LLPC cohort with an AUC of 0.82 (CI, 0.80 to 0.85).24 The Bach, Spitz, LLP and PLCOm2012 risk models were externally validated in the EPIC-German cohort of 20,700 ever smokers. The PLCOM2012 model showed the best performance in external validation (C-index: 0.81; 95% CI, 0.76-0.86) and the highest sensitivity, specificity, and PPV, however, the superiority over the Bach model and the LLP model was considered modest by the authors.27

Recently, five different risk models have been compared utilising data from the PLCO and NLST datasets.28 Even though a number of sophisticated models have utilised a range of risk variables (i.e. family history, previous malignancy, previous respiratory disease, exposure to asbestos), the Bach model still proved to have a good sensitivity and specificity,29 and it only uses age and smoking history in calculating the risk score, emphasizing the dominance of these two risk factors. The PLCO2012 model also provided good results, however, one of the limitations of the analysis, is that this model was developed using the PLCO data set, so potentially there may be issues of over-fitting. However, all of the models were superior to the NLST selection criteria and the current USPSTF recommendations. The predicted risk of lung cancer was analysed in 95,882 ever-smokers aged 45 years in the Australian Up Study (2006–2009), was calculated using PLCOm2012 applied to baseline data, which showed good discrimination (AUC 0.80, 95% CI 0.78–0.81) and excellent calibration.30 Thus, it is essential that risk prediction models are used to select subjects for lung cancer screening. Cost effectiveness was shown to be improved in the higher risk groups so it follows that better risk prediction should also improve costs per life saved. There is no information on related cost effectiveness.28 We recognise that the aforementioned risk prediction models were based on non-European populations, realizing that lung cancer risk prediction may be influenced by loco regional differences. The EUPS does not recommend any specific risk prediction model, however either the PLCO2012 or the LLPv2 would suffice if screening was implemented today.

We have to be aware of the different European healthcare systems and the issues of utilising a risk stratification approach (i.e. Germany), where all individuals have a legal right of access to the available diagnostic and therapeutic techniques. However, it should be argued that it would be unethical to screen low risk patients, based on the harm-benefit considerations.

The risk profile of subjects is a valuable and cost-effective tool to identify those with preclinical disease that are eligible for screening.7,20 Integration of the risk profile with biomarker(s) or susceptibility genes could potentially improve the selection of subjects at higher level of risk for screening and/or for the management of the disease.31,32 Predictive biomarkers, such as microRNA, have been shown as potentially effective tools for the identification of susceptible subjects and future lung cancer cases,33–35 whilst bronchial-airway gene-expression classifier possibly could improve the diagnostic performance of bronchoscopy.34 Breath tests for lung cancer have to be considered a strong possibility and are currently being tested in a clinical trial.35,36

Identification of new biomarkers for screening will be a reason to implement cooperative research; the availability of large, high quality biobanks embedded in screening trials together with the radiomics analysis is a future opportunity.

1. **Harms and benefits associated with lung cancer screening**

*There are more benefits than harms from lung cancer screening, when screening is undertaken in those with sufficiently high risk*

Before implementation of lung cancer screening it should be beyond any doubt that the harms associated with lung cancer screening, such as over-diagnosis, surgery for benign lesions, psychological harm and radiation exposure are at acceptable levels.

Minimizing harms in CT screening is essential in order to maximize the clinical effectiveness of the intervention. Harms may be considered as physical or psychological. The ways in which physical harms can be reduced are by (i) ensuring that only those who are at sufficiently high risk to benefit are screened, (ii) reducing screening radiation dose to a minimum, (iii) effective management of abnormal findings, including nodules, suspected lung cancer and incidental findings. This is predicated on ensuring that there is a high level of clinical expertise available so that all aspects of CT screening and management of findings are completed to the highest standard. Thus, lung cancer screening should only be undertaken according to protocol and screening units and centres should be in a position to ensure rigorous quality control.

“LDCT screening can be carried out outside a clinical trial, provided it is offered within a dedicated program with quality control, in a centre with experience in CT screening, a large volume of thoracic oncology activity and multidisciplinary management of suspicious findings” and a well-developed minimally invasive thoracic surgery program. This approach is according to the ESMO and ESTS guidelines.37,38

Potential psychological harms can be reduced by the provision of information about CT screening presented in a language that is understood by the screenees, as well as detailed

information concerning abnormal findings, with accurate information about the probability of cancer, especially where findings are likely to be benign.

The potential physical harms should be provided to screenees in a clear manner, including radiation exposure,39 and harms from biopsy or resection of a benign lesion. However, radiation risk is likely to be overestimated, and will in the future be lower with the latest CT platforms with ultra-low dose technology. The European trials will provide data which will allow for a direct quantification of overdiagnosis. Rates of benign resection vary in clinical trials from 10% to at least 25% of total operations.7,10 The consensus is that we should be working towards a 10% figure or even lower, however, an optimal percentage has not established to date. It should be considered that the patient/physician dynamic is altered in the lung cancer screening setting compared to symptomatic individuals who present themselves to healthcare institutions.

Effective management includes the benefits of maximizing smoking cessation within CT screening programmes. Thus, it is important to inform current smokers of the dangers of continuing to smoke for the own general health and to ensure they are offered suitable support.40–42

1. **CT methodologies for early lung cancer detection.**

*Volume methodology should be utilised for the detection of early lung cancer by CT.*

In the NLST trial, a CT screen was regarded as positive if it showed any non-calcified nodule at least 4 mm in diameter. The American College of Radiology set up a Lung Cancer Screening Committee subgroup to develop Lung-RADS,43,44 in-order to have a quality assurance tool to standardize lung cancer screening CT reporting and also provide management recommendations. The rationale behind this initiative was the hope that it would assist in lung cancer screening CT nodule scan interpretation.

LungRADS performance was compared to the NLST screening trial data,45 which indicated that LungRADS substantially reduced the false positive result rate but also the sensitivity level decreased. Recently it has been recommended by Mehta et al. indicated that the LungRADS system needs to be revised and they faulted the system on the basis that it has never been studied in a prospective fashion. In addition, Li et al. have recently analysed the size and growth of pulmonary nodules, as a consequence of ‘rounding ’ methodology used in LungRADS.46 They concluded that rounding up the mean nodule diameter, which was used in LungRADS, increases the frequency of positive results and has a detrimental effect on the efficiency of lung cancer screening. Furthermore, LungRADS does not provide guidance on risk prediction models. The Brock score47 has been shown to be more accurate than baseline LungRADS criteria.48

An alternative method is to determine nodule volume using software for semi-automated segmentation, which enables an accurate estimation of nodule size after three-dimensional reconstruction (Figure 1). Volumetric analysis of CT detected nodules was initially recommended by Henschke et al in 1999,3 and has been further developed and validated within the NELSON and the UKLS trial. A recent comparative analysis on both the diameter and volume has been undertaken on the NELSON baseline participants with 2,240 non-calcified nodules. Minimum and maximum diameter within a single nodule varied by a median of 2.8mm, which is larger than the LungRADS cut off for nodule growth (increase in mean diameter >1.5mm). Nodules with a diameter between 8 to 10mm were represented in each of the five differing nodule volume categories (Figure 2).49

The recommendation for the future management of CT screen solid nodules is that semi-automatically derived volume and volume-doubling time should be used in preference to diameter measurements; the latter should only be used where volumetry is not technically possible.

1. **Lung cancer population screening prerequisites**

*National clinical screening standards are required for future lung cancer CT screening programmes.*

Accreditation for institutions and radiologists participating in lung cancer CT screening should include training and participation in quality assurance.

A central national registry for participants ensures that inclusion criteria are met. In this registry, other screening modalities, i.e. CT manufacturer dose, and results together with work-up results should be collected, which ensures that previous screens are available and quality control can be assured. The institutions providing a lung cancer screening service should be registered, have access to a participant registry as well as previous screens, providing a certified nodule evaluation software, and will deliver screening results and recommendations to the central participant registry. It is recommended that the European lung cancer community develop national registries, which potentially could be linked on a hub and spoke format, thus enabling international quality control and utilising the data to improve the provision of lung cancer screening throughout Europe over time.

National quality assurance boards should be set up which monitors the adherence to minimum technical standards and to standardized diagnostic criteria for screen-detected lung nodules, similar to the UK and European breast screening programmes,50–52 and are entitled to advise /intervene whenever basic requirements are not met. The lung cancer community should consider following the example of the Dutch breast screening service by organising national ‘Central Reading Centres’ of all CT screening programmes;52 as the local reading of CT screen scans would potentially have a major impact on routine radiology service delivery. This would also enable ongoing national quality assurance and the introduction of the forefront automated pulmonary nodule reading software.

Institutions participating in screening programmes require MDTs to be available providing access to all relevant specialities (pulmonologist, thoracic surgeon, radiologist, lung cancer nurse etc.) in which suspicious screening results may be discussed. They should regularly demonstrate to a quality assurance board that they continue to meet basic standards, similar to those proposed by RSNA.53

1. **Lung nodule management at baseline CT screening**

*Baseline CT screening programmes should be targeted to prevalent lung nodules.*

Management of prevalent lung nodules will largely depend on size criteria. Volumetry is essential, but diameter cut-offs will also need to be provided for cases where segmentation is not possible. Minimum standards will need to be met for lung cancer screening CT acquisition parameters to ensure the standardization of volumetric analysis (i.e. acquisition protocol regarding slice thickness, reconstruction interval and image reconstruction algorithm (kernel) as well as, clearly defining the low-radiation dose parameters).

Management should be based on the evidence from screening trials that have used volumetry such as the NELSON trial. In the original NELSON nodule management protocol, cut-offs for negative and positive screen results were 50 and 500mm3, respectively. Nodules within volume range of 50-500mm3 were classified as indeterminate. Based on lung cancer probability outcome results of the first two screening round of the NELSON study, these cut-offs could be optimized.54 E.g. for solid nodules <100mm3 return to annual screen (based on an annual screening programme), 100-300mm3 for repeat study in 3 months, >300mm3 for referral to MDT (Figure 3a).54 Detailed risk profiles have been provided by the NELSON group for both nodule volume and volume doubling time (<400 and 400-600 days - increased risk described in Figure 3b; no significant increased risk, >600 days), on lung cancer probability over a two year period (Figure 4),54 which provides guidance of the future follow–up interval for specific screenees. Recently, in-vivo evidence for growth patterns of screen-detected lung cancers demonstrated an exponential growth pattern which can be described by the VDT.55 Acknowledging that software packages give different estimates of solid nodule volume, commonly of the order of 20%, (Corresponding to a non-measurable 7% error in nodule diameter; absolute 0.4mm error,56 there may be merit in reducing the nodule threshold for a repeat study at 3 months to 80 mm3if the software is not phantom validated (Figure 3c).

For sub-solid nodules, surveillance should be favoured over intervention to avoid over-diagnosis. For all pure ground glass nodules and most partial solid nodules, return to annual screening will be the most likely recommendation. (Figure 3d).57 Knowledge and data from ongoing lung cancer screening projects will also be important for future optimization and refinement of nodule management protocols.

It should be noted that morphology assessment will also play a role in the management of solid nodules, e.g. clustered ill-defined nodules, which are more in keeping with inflammatory aetiology, or smooth peri-fissural nodules or intrapulmonary lymph nodes, which will require management not based purely on size criteria.58 There are a number of alternative work-up methods of screen-detected suspicious nodules >300mm3 at baseline: i.e. core needle biopsy, PET/CT and primary resection.

The management of the patient should be according to the risk of malignancy. As we have discussed, lower risk nodules, say those with a <10% risk of malignancy can be followed up with interval imaging but those with higher risk need further work-up, provided this is in line with the patient’s wishes after an informed discussion. Management options are, broadly, further surveillance, biopsy or treatment as the risk of malignancy increases.

The recent ESMO guidelines indicate that the cornerstone of treatment of potentially resectable lung cancer is surgical removal of the tumour.37 For those who are not willing to accept the risks, or are at very high risk, non-surgical curative therapy should be offered, either SABR, hypofractionated high-dose RT or image guided ablative therapy.37

1. **Incident screening rounds**

*The management of lung nodules at incident screening rounds.*

Although incident screening rounds will comprise the majority of the work in the early detection of lung cancer, until recently, research did not focus on incident nodules and their definition. The definition of incident lung nodules has varied widely between LDCT lung cancer screening trials.16,59–61 Incident nodules detected in high-risk individuals after baseline screening were either missed previously, or develop *de novo* in the time interval since the prior scan. In the case of a missed nodule, calculation of the volume doubling time is advised for further risk stratification. Newly developed nodules, on the other hand, entail a specific group of pulmonary nodules distinct from baseline nodules. With an annual incidence between 3% and 13% of participants, these nodules are regularly encountered in LDCT lung cancer screening.62–65 Contrary to baseline nodules, which may have been present for years before detection, new incident nodules are potentially fast-growing.66–69 This is reflected in a high cancer risk of 2-8% for participants with a new incident nodule.62,63,65,66 Because these nodules have comparably less time to grow before detected, baseline cut-off values are not applicable.66 This previously theoretical concept, that led to an adjustment of cut-off values for new incident nodules in several trials,45,63,69 has recently been confirmed for new solid incident nodules by the NELSON trial.66 Considering that a large proportion (37-57%) of new incident nodules are very small (below 50mm3 volume),62,65,66 volume measurement should be preferred since diameter measurements are far less precise and reproducible. Data from the NELSON trial suggest that new solid incident nodules <27mm3 volume (<1% lung cancer probability) represent a low risk group and may return to annual screen (based on an annual screening programme), new solid incident nodules 27-207mm3 volume (3% lung cancer probability) form an intermediate risk group requiring repeat LDCT in 3 months, and new non-calcified solid incident nodules ≥208mm3 volume (17% lung cancer probability) form a high risk group requiring referral to MDT.66 We suggest simplifying these categories to <30mm3, 30 to 200mm3 and ≥200mm3 (Figure 3b). The existing data indicates that the majority (68-86%) of lung cancers found in new incident nodules during lung cancer screening are detected at stage I,63,66 volume doubling time assessment at follow-up scans appears appropriate, such as outlined in the BTS guidelines.61 However, the current evidence body regarding new incident nodules is insufficient and a more standardized manner of reporting, for instance strictly separating baseline and incident nodules, could simplify the translation to routine clinical management of incidentally detected pulmonary nodules. If a previous CT scan <2 years ago is available, recommendations for screen detected new incidence nodules could be extrapolated to routine clinical practice in a high-risk patient population, similar to the NELSON trial. This has now been adopted from the BTS guideline nodule management,70 and in the BTS Quality Standard on Lung Nodule management (Thorax, 2017 in press). In a lower risk patient population, management should follow the BTS guidelines.

1. **Clinical workup of CT detected lung nodules in clinical practice.**

*In clinical practice the preferred initial and subsequent management should be based on the lung cancer probability of the CT detected lung nodules.*

Incidentally detected lung nodules are an increasingly common clinical problem arising from the increased use of cross-sectional imaging in clinical practice. The British Thoracic Society (BTS) has undertaken an in-depth piece of work developing guidelines on the management of pulmonary nodules in a clinical context and not in the context of population screening.61 This work has been based on extensive review of the literature and the utilisation of recent publications from a number of lung cancer CT screening trials and in-depth analysis of the data. The Guideline Development Group (GDG) used methodology compliant with AGREE Collaboration criteria and standards set by NHS Evidence. The evidence review was comprehensive, conducted in November 2012 and updated in June 2014. The guidelines provide four management algorithms and two malignancy prediction tools.61 The Brock risk prediction tool to calculate malignancy in solid pulmonary nodules ≥5 mm, which are unchanged at three months47 and the Herder prediction tool to be used after PET-CT71 (Figure 3c).

Furthermore, volumetry has been recommended by BTS as the preferred measurement method of CT detected nodules. The guideline also provides recommendations for the management of nodules with extended volume doubling times.

The BTS guidelines provide recommendations on the use of further imaging, and the use of PET-CT information which can be incorporated into pulmonary risk models (Herder model), as well as advice on biopsy and the threshold for treatment without histological confirmation. BTS provides advice on the information which should be given to patients on the management of pulmonary nodules in a non-screening context. The EUPS recommends keeping a database of all nodules that can facilitate future refinement of nodule management in line with new evidence.

1. **Optimal timing of lung cancer screening intervals**

*Screen interval depends on the baseline and subsequent risk of lung cancer.*

The US Preventive Services Task Force (USPSTF) on CT screening has recommended screening yearly from the age of 55 to 80 years.72 In a recent NELSON publication, a 2.5 year screening interval resulted in a significant increase in interval cancers in the fourth screening round, thus arguing against using such an interval in a future screening programme.73 There were significantly more interval cancers in the 2 year time frame and still a trend towards less early stage disease and detailed cost effectiveness of various screening scenarios has demonstrated that almost all scenarios are most cost effective when screens are annual.74 However, in the NELSON trial, in half of the included participants no pulmonary nodules were detected and their 2-year probability of developing lung cancer was 0∙4%, thereby indicating that a screening interval of up to 2 years, could be considered for similar individuals in future screening programmes, a risk stratified approach. The only trial to test annual and biennial screening was the MILD trial, where no difference was found in terms of mortality when comparing these two screening intervals.75

Screening intervals have been modelled by both the ULKS and IELCAP.76,77 Duffy et al. acknowledged the risk of increasing the number of interval cancers but potentially providing a more cost-effective approach. Yankelevitz at al.77 argued that we have to move beyond hypothesis-testing and on to quantification. We need to learn how the length of the interval between screens affects the diagnostic distribution before we consider changing annual screening intervals.

Currently we only have trial evidence for annual screening. Recent studies have shown that previous negative screening results may provide directions for further risk stratification.78,79 Future decisions regarding the screen interval timing should be based on risk, psychosocial impact,80 cost-effectiveness and the feasibility of implementation,81 but these areas require further investigations. However, with newer, ultra-low dose CT techniques, the radiation dose for repeated CT screenings over a 30-year period, may not be a major issue for the screenees. New developments such as deep learning will assist us in the automation of pulmonary nodule management of lung cancer screening.82

In the future, there will be an issue for screening high risk individuals every year, over a 25 year period. We should be considering precision medicine in the field of lung cancer screening and whether an individual who has had a negative baseline and year one scan, should be moved into biennial screening, until their risk profile changes. Lung cancer screening is still in an embryonic stage of implementation in Europe and thus we have an opportunity to plan to develop an optimal lung cancer LDCT screening strategy.83

**Conclusions**

The EUPS describes the current status of lung cancer screening in Europe. Through consensus discussions with experts from the eight European countries undertaking RCT lung cancer CT screening trials, we have developed nine recommendations to guide the implementation of lung cancer screening in Europe. It is recognised that there remain specific areas which require further development and consideration (i.e. integrating smoking cessation and selection of the screening population), however, the weight of evidence clearly points to the imperative for Europe to start planning for implementation within the next 18 months as outlined in the EUPS ‘Call for Action’. During this planning period, the focus for each country will be to decide on the best risk prediction methodology to identify and recruit the high-risk population and also to set up the required infrastructure for quality controlled CT scans, utilising volumetric analysis. The EUPS has provided detailed recommendations on the management of lung nodules by lung cancer MDTs, with the aim to minimise harm and ensure patients receive the optimal diagnosis and therapy.

References

1. Fontana RS, Sanderson DR, Woolner LB, Taylor WF, Miller WE, Muhm JR. Lung cancer screening: the Mayo program. *J Occup Med* 1986; **28**(8): 746-50.

2. Oken MM, Hocking WG, Kvale PA, et al. Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. *JAMA* 2011; **306**(17): 1865-73.

3. Henschke CI, McCauley DI, Yankelevitz DF, et al. Early Lung Cancer Action Project: overall design and findings from baseline screening. *Lancet* 1999; **354**(9173): 99-105.

4. Biederer J, Ohno Y, Hatabu H, et al. Screening for lung cancer: Does MRI have a role? *Eur J Radiol* 2017; **86**: 353-60.

5. National Lung Screening Trial Research T, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. *N Engl J Med* 2011; **365**(5): 395-409.

6. van Klaveren RJ, Oudkerk M, Prokop M, et al. Management of lung nodules detected by volume CT scanning. *N Engl J Med* 2009; **361**(23): 2221-9.

7. Field JK, Duffy SW, Baldwin DR, et al. The UK Lung Cancer Screening Trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer. *Health Technol Assess* 2016; **20**(40): 1-146.

8. Becker N, Motsch E, Gross ML, et al. Randomized Study on Early Detection of Lung Cancer with MSCT in Germany: Results of the First 3 Years of Follow-up After Randomization. *J Thorac Oncol* 2015; **10**(6): 890-6.

9. Horeweg N, van der Aalst CM, Vliegenthart R, et al. Volumetric computed tomography screening for lung cancer: three rounds of the NELSON trial. *Eur Respir J* 2013; **42**(6): 1659-67.

10. Sverzellati N, Silva M, Calareso G, et al. Low-dose computed tomography for lung cancer screening: comparison of performance between annual and biennial screen. *Eur Radiol* 2016; **26**(11): 3821-9.

11. Field JK, Oudkerk M, Pedersen JH, Duffy SW. Prospects for population screening and diagnosis of lung cancer. *Lancet* 2013; **382**(9893): 732-41.

12. Infante M, Cavuto S, Lutman FR, et al. Long-Term Follow-up Results of the DANTE Trial, a Randomized Study of Lung Cancer Screening with Spiral Computed Tomography. *Am J Respir Crit Care Med* 2015; **191**(10): 1166-75.

13. Wille MM, Dirksen A, Ashraf H, et al. Results of the Randomized Danish Lung Cancer Screening Trial with Focus on High-Risk Profiling. *Am J Respir Crit Care Med* 2016; **193**(5): 542-51.

14. Paci E, Puliti D, Lopes Pegna A, et al. Mortality, survival and incidence rates in the ITALUNG randomised lung cancer screening trial. *Thorax* 2017.

15. Infante M, Sestini S, Galeone C, et al. Lung cancer screening with low-dose spiral computed tomography: evidence from a pooled analysis of two Italian randomized trials. *Eur J Cancer Prev* 2016.

16. Field JK, van Klaveren R, Pedersen JH, et al. European randomized lung cancer screening trials: Post NLST. *J Surg Oncol* 2013; **108**(5): 280-6.

17. Cressman S, Peacock SJ, Tammemagi MC, et al. The Cost-Effectiveness of High-Risk Lung Cancer Screening and Drivers of Program Efficiency. *J Thorac Oncol* 2017.

18. Gonzalez J, Marin M, Sanchez-Salcedo P, Zulueta JJ. Lung cancer screening in patients with chronic obstructive pulmonary disease. *Ann Transl Med* 2016; **4**(8): 160.

19. Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 2012; **380**(9859): 2197-223.

20. Tammemagi MC, Katki HA, Hocking WG, et al. Selection criteria for lung-cancer screening. *N Engl J Med* 2013; **368**(8): 728-36.

21. Kovalchik SA, Tammemagi M, Berg CD, et al. Targeting of low-dose CT screening according to the risk of lung-cancer death. *N Engl J Med* 2013; **369**(3): 245-54.

22. Katki HA, Kovalchik SA, Berg CD, Cheung LC, Chaturvedi AK. Development and Validation of Risk Models to Select Ever-Smokers for CT Lung Cancer Screening. *JAMA* 2016.

23. Cassidy A, Myles JP, van Tongeren M, et al. The LLP risk model: an individual risk prediction model for lung cancer. *Br J Cancer* 2008; **98**(2): 270-6.

24. Raji OY, Duffy SW, Agbaje OF, et al. Predictive accuracy of the Liverpool Lung Project risk model for stratifying patients for computed tomography screening for lung cancer: a case-control and cohort validation study. *Ann Intern Med* 2012; **157**(4): 242-50.

25. Field JK, Gaynor ES, Duffy SW, et al. Liverpool healthy lung project: A primary care initiative to identify hard to reach individuals with a high risk of developing lung cancer. . *AACR* 2017; **S 4220**.

26. Field JK, Marcus M, Maroni R, et al. Liverpool Healthy Lung project. 2017. <http://www.liverpoolccg.nhs.uk/health-and-services/healthy-lungs/> (accessed 06-09-2017.

27. Li K, Husing A, Sookthai D, et al. Selecting High-Risk Individuals for Lung Cancer Screening: A Prospective Evaluation of Existing Risk Models and Eligibility Criteria in the German EPIC Cohort. *Cancer Prev Res (Phila)* 2015; **8**(9): 777-85.

28. Ten Haaf K, Jeon J, Tammemagi MC, et al. Risk prediction models for selection of lung cancer screening candidates: A retrospective validation study. *PLoS Med* 2017; **14**(4): e1002277.

29. Bach PB, Kattan MW, Thornquist MD, et al. Variations in lung cancer risk among smokers. *J Natl Cancer Inst* 2003; **95**(6): 470-8.

30. Weber M, Yap S, Goldsbury D, et al. Identifying high risk individuals for targeted lung cancer screening: Independent validation of the PLCOm2012 risk prediction tool. *Int J Cancer* 2017; **141**(2): 242-53.

31. Hung RJ, McKay JD, Gaborieau V, et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. *Nature* 2008; **452**(7187): 633-7.

32. Amos CI, Dennis J, Wang Z, et al. The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers. *Cancer Epidemiol Biomarkers Prev* 2017; **26**(1): 126-35.

33. Sestini S, Boeri M, Marchiano A, et al. Circulating microRNA signature as liquid-biopsy to monitor lung cancer in low-dose computed tomography screening. *Oncotarget* 2015; **6**(32): 32868-77.

34. Silvestri GA, Vachani A, Whitney D, et al. A Bronchial Genomic Classifier for the Diagnostic Evaluation of Lung Cancer. *N Engl J Med* 2015; **373**(3): 243-51.

35. Broza YY, Kremer R, Tisch U, et al. A nanomaterial-based breath test for short-term follow-up after lung tumor resection. *Nanomedicine* 2013; **9**(1): 15-21.

36. LuCID -A multi-centre prospective trial for lung cancer screening. 2016. <https://www.owlstonemedical.com/clinical-pipeline/lucid/> (accessed 01-07-2017.

37. Postmus PE, Kerr KM, Oudkerk M, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Internal Med (in Press)* 2017.

38. Pedersen JH, Rzyman W, Veronesi G, et al. Recommendations from the European Society of Thoracic Surgeons (ESTS) regarding computed tomography screening for lung cancer in Europe. *Eur J Cardiothorac Surg* 2017; **51**(3): 411-20.

39. Rampinelli C, De Marco P, Origgi D, et al. Exposure to low dose computed tomography for lung cancer screening and risk of cancer: secondary analysis of trial data and risk-benefit analysis. *BMJ* 2017; **356**: j347.

40. Tammemagi MC, Berg CD, Riley TL, Cunningham CR, Taylor KL. Impact of lung cancer screening results on smoking cessation. *J Natl Cancer Inst* 2014; **106**(6): dju084.

41. Ashraf H, Tonnesen P, Holst Pedersen J, Dirksen A, Thorsen H, Dossing M. Effect of CT screening on smoking habits at 1-year follow-up in the Danish Lung Cancer Screening Trial (DLCST). *Thorax* 2009; **64**(5): 388-92.

42. Brain K, Carter B, Lifford KJ, et al. Impact of low-dose CT screening on smoking cessation among high-risk participants in the UK Lung Cancer Screening Trial. *Thorax* 2017.

43. Fintelmann FJ, Bernheim A, Digumarthy SR, et al. The 10 Pillars of Lung Cancer Screening: Rationale and Logistics of a Lung Cancer Screening Program. *Radiographics* 2015; **35**(7): 1893-908.

44. McKee BJ, Regis SM, McKee AB, Flacke S, Wald C. Performance of ACR Lung-RADS in a Clinical CT Lung Screening Program. *J Am Coll Radiol* 2016; **13**(2 Suppl): R25-9.

45. Pinsky PF, Gierada DS, Black W, et al. Performance of Lung-RADS in the National Lung Screening Trial: A Retrospective Assessment. *Ann Intern Med* 2015.

46. Li K, Yip R, Avila R, Henschke CI, Yankelevitz DF. Size and Growth Assessment of Pulmonary Nodules: Consequences of the Rounding. *J Thorac Oncol* 2016.

47. McWilliams A, Tammemagi MC, Mayo JR, et al. Probability of cancer in pulmonary nodules detected on first screening CT. *N Engl J Med* 2013; **369**(10): 910-9.

48. van Riel SJ, Ciompi F, Jacobs C, et al. Malignancy risk estimation of screen-detected nodules at baseline CT: comparison of the PanCan model, Lung-RADS and NCCN guidelines. *Eur Radiol* 2017.

49. Heuvelmans M. Nodule Size is Poorly Represented by Nodule

Diameter in Low–Dose CT Lung Cancer Screening. *Proceedings World Confernce Lung Cancer 2016* 2016; **P1.03–042:**.

50. England PH. NHS Breast Screening Programme Consolidated standards. NHS England; 2017.

51. Perry N, Broeders M, de Wolf C, Tornberg S, Holland R, von Karsa L. European guidelines for quality assurance in breast cancer screening and diagnosis. Fourth edition--summary document. *Ann Oncol* 2008; **19**(4): 614-22.

52. LCRB. LCRB Dutch Breast cancer- focus on early disease. 2017. <http://www.lrcb.nl/en/breast-cancer/audit/> (accessed 15-05-2017 2017).

53. RSNA. Lung Nodule Volume Assessment and Monitoring in Low Dose CT Screening RSNA. *CT Volumetry Technical Committee Lung Nodule Assessment in CT Screening Profile, Quantitative Imaging Biomarkers Alliance* 2016; **Version 1.0. Reviewed draft. QIBA**.

54. Horeweg N, van Rosmalen J, Heuvelmans MA, et al. Lung cancer probability in patients with CT-detected pulmonary nodules: a prespecified analysis of data from the NELSON trial of low-dose CT screening. *Lancet Oncol* 2014; **15**(12): 1332-41.

55. Heuvelmans MA, Vliegenthart R, de Koning HJ, et al. Quantification of growth patterns of screen-detected lung cancers: The NELSON study. *Lung Cancer* 2017; **108**: 48-54.

56. de Hoop B, Gietema H, van Ginneken B, Zanen P, Groenewegen G, Prokop M. A comparison of six software packages for evaluation of solid lung nodules using semi-automated volumetry: what is the minimum increase in size to detect growth in repeated CT examinations. *Eur Radiol* 2009; **19**(4): 800-8.

57. Scholten ET, de Jong PA, Jacobs C, et al. Interscan variation of semi-automated volumetry of subsolid pulmonary nodules. *Eur Radiol* 2015; **25**(4): 1040-7.

58. Chung K, Jacobs C, Scholten ET, et al. Lung-RADS Category 4X: Does It Improve Prediction of Malignancy in Subsolid Nodules? *Radiology* 2017: 161624.

59. Midthun DE, Jett JR. Screening for lung cancer: the US studies. *J Surg Oncol* 2013; **108**(5): 275-9.

60. Bach PB, Mirkin JN, Oliver TK, et al. Benefits and harms of CT screening for lung cancer: a systematic review. *JAMA* 2012; **307**(22): 2418-29.

61. Callister ME, Baldwin DR, Akram AR, et al. British Thoracic Society guidelines for the investigation and management of pulmonary nodules. *Thorax* 2015; **70 Suppl 2**: ii1-ii54.

62. Henschke CI, Naidich DP, Yankelevitz DF, et al. Early lung cancer action project: initial findings on repeat screenings. *Cancer* 2001; **92**(1): 153-9.

63. Henschke CI, Yankelevitz DF, Libby DM, Pasmantier MW, Smith JP, Miettinen OS. Survival of patients with stage I lung cancer detected on CT screening. *N Engl J Med* 2006; **355**(17): 1763-71.

64. Wilson DO, Weissfeld JL, Fuhrman CR, et al. The Pittsburgh Lung Screening Study (PLuSS): outcomes within 3 years of a first computed tomography scan. *Am J Respir Crit Care Med* 2008; **178**(9): 956-61.

65. Swensen SJ, Jett JR, Sloan JA, et al. Screening for lung cancer with low-dose spiral computed tomography. *Am J Respir Crit Care Med* 2002; **165**(4): 508-13.

66. Walter JE, Heuvelmans MA, de Jong PA, et al. Occurrence and lung cancer probability of new solid nodules at incidence screening with low-dose CT: analysis of data from the randomised, controlled NELSON trial. *Lancet Oncol* 2016; **17**(7): 907-16.

67. Henschke CI, Yankelevitz DF, Yip R, et al. Lung cancers diagnosed at annual CT screening: volume doubling times. *Radiology* 2012; **263**(2): 578-83.

68. Carter D, Vazquez M, Flieder DB, et al. Comparison of pathologic findings of baseline and annual repeat cancers diagnosed on CT screening. *Lung Cancer* 2007; **56**(2): 193-9.

69. Xu DM, Yip R, Smith JP, Yankelevitz DF, Henschke CI, Investigators IE. Retrospective review of lung cancers diagnosed in annual rounds of CT screening. *AJR Am J Roentgenol* 2014; **203**(5): 965-72.

70. Pulmonary Nodule Risk 2017. <https://itunes.apple.com/gb/app/pulmonary-nodule-risk/id1142255949?mt=8>, (accessed 15-05-2017 2017).

71. Herder GJ, van Tinteren H, Golding RP, et al. Clinical prediction model to characterize pulmonary nodules: validation and added value of 18F-fluorodeoxyglucose positron emission tomography. *Chest* 2005; **128**(4): 2490-6.

72. USPSTF. USPSTF Lung Cancer Screening 25-11-2016 2015. <http://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/lung-cancer-screening> (accessed 26- 07-2017.

73. Yousaf-Khan U, van der Aalst C, de Jong PA, et al. Final screening round of the NELSON lung cancer screening trial: the effect of a 2.5-year screening interval. *Thorax* 2017; **72**(1): 48-56.

74. Ten Haaf K, Tammemagi MC, Bondy SJ, et al. Performance and Cost-Effectiveness of Computed Tomography Lung Cancer Screening Scenarios in a Population-Based Setting: A Microsimulation Modeling Analysis in Ontario, Canada. *PLoS Med* 2017; **14**(2): e1002225.

75. Pastorino U, Rossi M, Rosato V, et al. Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial. *Eur J Cancer Prev* 2012; **21**(3): 308-15.

76. Duffy SW, Field JK, Allgood PC, Seigneurin A. Translation of research results to simple estimates of the likely effect of a lung cancer screening programme in the United Kingdom. *Br J Cancer* 2014; **110**(7): 1834-40.

77. Yankelevitz D, Henschke C. Lung cancer: Low-dose CT screening - determining the right interval. *Nat Rev Clin Oncol* 2016; **13**(9): 533-4.

78. Yousaf-Khan U, van der Aalst C, de Jong PA, et al. Risk stratification based on screening history: the NELSON lung cancer screening study. *Thorax* 2017.

79. Patz EF, Jr., Greco E, Gatsonis C, Pinsky P, Kramer BS, Aberle DR. Lung cancer incidence and mortality in National Lung Screening Trial participants who underwent low-dose CT prevalence screening: a retrospective cohort analysis of a randomised, multicentre, diagnostic screening trial. *Lancet Oncol* 2016; **17**(5): 590-9.

80. Dunn CE, Edwards A, Carter B, Field JK, Brain K, Lifford KJ. The role of screening expectations in modifying short-term psychological responses to low-dose computed tomography lung cancer screening among high-risk individuals. *Patient education and counseling* 2017; **100**(8): 1572-9.

81. Field JK, Duffy SW, Devaraj A, Baldwin DR. Implementation planning for lung cancer screening: five major challenges. *Lancet Respir Med* 2016; **4**(9): 685-7.

82. Ciompi F, Chung K, van Riel SJ, et al. Towards automatic pulmonary nodule management in lung cancer screening with deep learning. *Sci Rep* 2017; **7**: 46479.

83. Field JK. Perspective: The screening imperative. *Nature* 2014; **513**(7517): S7.

Figure Legends

Figure 1

Upper figure legend

A volume growth of 26 % , defined as growth by NELSON criteria, is hardly appreciable by diameter measurement (8 % diameter increase which is NO growth by current criteria)

Lower figure legend.

A 25% diameter increase i.e. threshold for the current growth definition reflects almost a doubling in volume ( 95%). It reflects the insensitivity for growth of diameter measurement

Reproduced from :

Field et al. Prospects for population screening and diagnosis of lung cancer. Lancet. 2013;382(9893):732-41.

Figure 2. Range in mean axial nodule diameter per nodule category. Nodules with mean diameter between 8 and 10 mm (coloured zone) are represented in each volume category. These nodules represent the category with highest uncertainty about nodule nature. The data in this figure is based on intermediate-sized baseline nodules only.

Figure 3 Nodule Management Protocol

Fig 3a Nodule management protocol for screen detected solid nodules at baseline.

For nodules with volume-doubling time (VDT) between 400 and 600 days (intermediate cancer risk of ~4%), a second repeat CT in 3 months should be considered as an initial workup option.

Fig 3b Nodule management protocol for screen detected incidental solid nodules at follow-up.

Fig 3c Nodule management protocol for clinically detected solid nodules

Fig 3d Nodule management protocol for subsolid nodules for both screen detected and clinically detected

Figure 3c an 3d reproduced from :

Callister ME, Baldwin DR, Akram AR, Barnard S, Cane P, Draffan J, et al. British Thoracic Society guidelines for the investigation and management of pulmonary nodules. Thorax. 2015;70 Suppl 2:ii1-ii54.

Figure 4

Contour plot of the effect of the combined effect of nodule volume and volume doubling times on 2-year lung cancer probability.

Reproduced from:

Horeweg et al. Lung cancer probability in patients with CT-detected pulmonary nodules: a prespecified analysis of data from the NELSON trial of low-dose CT screening. Lancet Oncol. 2014;15(12):1332-41.

**Search strategy and selection criteria**

Data for this EU Position Statement were identified searches of PubMed, Medline, and references from relevant articles using search terms lung cancer CT screening trial’, ’lung screen detected nodules’, ‘lung cancer CT screening recommendations’, ‘lung cancer CT screening cost effectiveness’. Abstracts and reports from meetings were included only when they related directly to previous published work. Only articles published in English between 1999 and 2017 were included.

Authors Conflict of Interest Statements

Dr. Bastarrika reports other from BAYER, other from GENERAL ELECTRIC, other from SIEMENS HEALTHCARE, outside the submitted work.

Dr.D. R. Baldwin reports personal fees from Astra Zeneca, outside the submitted work.

Dr. Delorme reports grants from German Research Foundation, grants from Dietmar Hopp Foundation, during the conduct of the study.

Professor J.K. Field reports grants from HTA funding for the UKLS trial, grants and other from Liverpool CCG, other from Epigenomics, other from Vision Gate, outside the submitted work.

Dr. C. P. Heussel reports: Consultation or other fees Pfizer 2014; Boehringer Ingelheim 2014; Novartis 2014; Gilead 2015; MSD 2013; Intermune 2014; Fresenius 2014. Research funding Siemens 2012-2014; Pfizer 2012-2014; Boehringer Ingelheim 2014. Lecture fees Gilead 2014; MSD 2014; Pfizer 2014; Intermune 2014; Novartis 2013-2016; Basilea 2015, 2016; Bayer 2016.

Dr. Infante reports personal fees from Exact Sciences Madison WN USA, outside the submitted work.

Professor H. de Koning reports grants from NELSON, grants from NELSON, grants from NELSON, non-financial support from NELSON, from null, outside the submitted work; and ‘Health Technology Assessment for CT Lung Cancer Screening in Canada’. Cancer Care Ontario, dr. Paszat. Grant. HJdK took part in a 1-day advisory meeting on biomarkers organized by M.D. Anderson/Health Sciences during the 16th World Conference on Lung Cancer. HJdK received a grant from the University of Zurich to assess the cost-effectiveness of computed tomographic lung cancer screening in Switzerland.

Professor M. Oudkerk reports grants from Royal Dutch Academy of Sciences, grants from The Netherlands Organisation for Scientific research (NOW). Grants from The Netherlands

Organisation for Health research and Development, outside the submitted work.

Dr. Sverzellati reports personal fees from ROCHE, personal fees from, personal fees from BOEHRINGER INGELHEIM, personal fees from PAREXEL, personal fees from BAYER, outside the submitted work.

Dr Rzyman reports he has a patent protein marker signature of early lung cancer pending and a patent miRNA signature of early lung cancer.

The other authors declared no conflicts of interest

**Authors contribution:**

Matthijs Oudkerk & John K. Field developed the concept and design of the EU Position Statement on Lung Cancer Screening

All of the authors contributed equally to developing the EU Position Statement on Lung Cancer Screening.

Matthijs Oudkerk

Anand Devaraj

Rozemarijn Vliegenthart

Thomas Henzler

Helmut Prosch

Claus Peter Heussel

Gorka Bastarrika

Nicola Sverzellati

Mario Mascalchi

Stefan Delorme

Matthew Callister

David R Baldwin

Marjolein A Heuvelmans

Nikolaus Becker

Witold Rzyman

Maurizio V. Infante

Ugo Pastorino

Jesper Holst Pedersen

Eugino Paci

Stephen W. Duffy

Harry de Koning

John K. Field

Funding: N/A